Long-term outcomes of durvalumab after chemoradiotherapy in locally advanced non-small cell lung cancer in Russia

• Published in: Medicinskij sovet no. 10; pp. 37 - 44
• Main Authors: Yudin, D. I., Laktionov, К. К., Moiseenko, F. V., Ponomarenko, D. M., Сhernykh, M. V., Chubenko, V. A., Levchenko, N. V., Kozlov, V. V., Stepanova, E. О., Khagazheeva, M. N., Yukalchuk, D. Yu
• Format: Journal Article
• Language: English
• Published: 24-07-2024
• DOI: 10.21518/ms2024-241
• EISSN: 2658-5790
• ISSN: 2079-701X

Introduction. The results of the PACIFIC trial have changed the standards of care for the patients with unresectable stage III nonsmall cell lung cancer (NSCLC). However, many patients in our clinical practice do not meet the inclusion criteria of PACIFIC trial.
Aim. To evaluate the long-term outcomes for this approach in real clinical practice in Russia.
Materials and м ethods . This real-world observational retrospective multicenter study analyzed clinical outcomes in 100 patients with unresectable stage III NSCLC after concurrent or sequential chemoradiotherapy (CRT). The overall survival (OS) and progression-free survival (PFS) were evaluated by the Kaplan-Meyer method. Multivariate subgroups analysis was performed as well. The median follow-up time was 22.7 months.
Results . There were 96% patients with ECOG/WHO performance status 0 or 1 in our study. Most of the patients were treated by sequential CRT (76%). Median time of durvalumab start from the end of CRT was 34 days. Patients received durvalumab for a median 10 months. The estimated median progression-free survival (PFS) and overall survival (OS) were 14.3 months (11.8–16.7, 95% CI) and 29 months (18.7–39.2, 95% CI), respectively. The estimated 1-year and 2-year rates for OS and for PFS were 90.4%, 62.8% and 59.1%, 35%, respectively. In multivariate analysis, a smoking history (HR = 0.21 (0.10–0.45; 95% CI) and concurrent CRT (HR = 0.3 (0.12–0.74; 95%CI) were associated with better PFS. The smoking history was significantly associated with a better OS (HR = 0.29 (0.10–0.76; 95% CI)) as well.
Conclusions. There is a difference between the real-world outcomes for patients with unresectable stage III NSCLC in Russia and the PACIFIC trial. Sequential CRT is the most frequent treatment option for locally advanced unresectable NSCLC in Russia, and estimated OS and PFS are shorter than in the PACIFIC clinical trial. A paradigm shift in chemoradiotherapy to the concurrent and personalized approach could change the current situation.